Moderate immune response is more effective against leukemia
The development of immunotherapies against blood cancer could be more successful if T cells are activated moderately rather than excessively. Scientists from the German Cancer Research Center have now been able to show this in mice: If the researchers blocked a cytokine that slows down the immune system, the T cells became exhausted and failed in the fight against leukemia.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/moderate-immune-response-more-effective-against-leukemia
At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-developed-predict-response-immunotherapies-lung-cancer
Search terms study